Pfiz­er doles out $2.3B for blood can­cer play­er to flesh out its end-of-decade on­col­o­gy port­fo­lio

As its Covid-19 vac­cine rakes in cash, Pfiz­er is in a po­si­tion to move bold­ly as it looks at the hazy end of the cur­rent decade. Seek­ing peace of mind, the drug­mak­er has signed a rich deal with a fa­mil­iar CD47 play­er to help firm up its next-gen game plans.

Pfiz­er will pay $2.26 bil­lion to ac­quire Cana­di­an biotech Tril­li­um Ther­a­peu­tics and its lead mol­e­cules tar­get­ing the sig­nal reg­u­la­to­ry pro­tein-α (SIR­Pα)–CD47 ax­is for blood can­cers as part of a push to add fire­pow­er to the Big Phar­ma’s on­col­o­gy port­fo­lio for the late 2020s, the part­ners said in a re­lease Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER